Serine Hydroxymethyltransferase Activity and Protein Detection

High‑Precision Serine Hydroxymethyltransferase (SHMT) Activity and protein detection for One‑Carbon Metabolism Research, Drug Discovery, and Clinical Biomarker Studies

Serine hydroxymethyltransferase (SHMT, EC 2.1.2.1) is a key enzyme in one‑carbon metabolism that catalyses the reversible conversion of serine and tetrahydrofolate (THF) to glycine and 5,10‑methylene‑THF, a crucial one‑carbon donor for nucleotide synthesis, methylation reactions, and redox homeostasis. SHMT exists in cytosolic (SHMT1) and mitochondrial (SHMT2) isoforms, which play distinct roles in cell proliferation, serine/glycine metabolism, and the adaptation to metabolic stress. Dysregulation of SHMT activity is closely associated with cancer, liver diseases, neurological disorders, and congenital anomalies, making it a significant biomarker and a promising therapeutic target. The accurate and comprehensive characterisation of SHMT—including enzyme activity, kinetic parameters, protein abundance, isoform discrimination, and inhibitor sensitivity—is essential for metabolic research, drug development, clinical diagnostics, and quality control of biological reagents. Our specialised detection platform offers a fully validated suite of biochemical, mass spectrometric, and functional assays tailored to SHMT from human, animal, microbial, and recombinant sources, delivering the high‑precision, regulatory‑ready data that clients require for research, development, and compliance.

Scientific and Translational Rationale for SHMT Analysis

Clients seeking SHMT detection services are driven by a range of strategic objectives. In cancer and metabolic research, the primary need is to quantify SHMT activity and protein levels in tumour tissues, cell lines, and biofluids to assess the dependency of cancer cells on one‑carbon metabolism and to evaluate the effects of metabolic interventions. In drug discovery and pharmacology, measuring the inhibitory potency of novel compounds against SHMT isoforms is critical for identifying selective inhibitors with therapeutic potential in oncology and antifolate drug development. In clinical diagnostics and biomarker studies, SHMT expression and activity levels are emerging as biomarkers for disease progression and treatment response. In nutritional and folate research, SHMT activity reflects the functional status of one‑carbon metabolism and the cellular response to folate deficiency or supplementation. In quality control of enzyme preparations, verifying the activity and purity of recombinant SHMT standards is essential for assay development and diagnostic kit production. In regulatory submissions, comprehensive data on enzyme activity, selectivity, and stability are required for the approval of novel therapeutics and diagnostic tools. Our service is architected to address these diverse needs with a flexible, ISO 17025‑accredited analytical framework that adapts to the specific isoform, sample matrix, and client's research or regulatory context.

Integrated Analytical Platform for Holistic SHMT Characterisation

Our analytical platform comprises four interconnected modules that collectively deliver a comprehensive evaluation of SHMT quality and performance. The Activity Quantification Module employs a range of validated assays, including the continuous spectrophotometric assay monitoring the formation of glycine from serine (or the reverse reaction) coupled to a glycine oxidase or dehydrogenase, and the fluorometric assay using a fluorescent substrate analogue. We determine the specific activity (U/mg protein) with precision within ±2% RSD and a limit of detection (LOD) as low as 0.001 U/mL. For detailed kinetic characterisation, we calculate Michaelis‑Menten parameters (K_m for serine and THF, V_max, k_cat) and inhibition constants for a panel of known inhibitors (e.g., antifolates, glycine analogues), with 95% confidence intervals typically within ±5%. The Isoform and Protein Quantitation Module uses ELISA with isoform‑specific antibodies (e.g., anti‑SHMT1, anti‑SHMT2) to quantify protein abundance, providing LOQs of 0.05 ng/mg of total protein and inter‑assay precision < 5%. For absolute quantitation and isoform discrimination, we use LC‑MS/MS‑based targeted proteomics (PRM) with stable isotope‑labelled peptide standards, achieving LOQs in the low fmol/mg range and enabling the simultaneous quantitation of both isoforms in a single run. The Subcellular Localisation Module employs subcellular fractionation followed by activity and protein quantitation to determine the distribution of SHMT between cytosolic and mitochondrial compartments. The Inhibitor and Drug Interaction Module evaluates the effect of test compounds on SHMT activity using the primary activity assay, providing IC₅₀ values, mechanism‑of‑action analysis (competitive, uncompetitive, mixed), and binding affinity measurements by surface plasmon resonance (SPR) or isothermal titration calorimetry (ITC), with K_D values in the low nM range. The Stability and Formulation Module subjects the enzyme to accelerated aging conditions (temperatures from 2°C to 40°C, pH 5‑9, and various ionic strengths) and monitors residual activity, aggregation (by SEC‑HPLC), and conformational integrity (by CD spectroscopy) over time. Using Arrhenius modelling and deactivation kinetics, we predict shelf‑life and identify critical degradation pathways (e.g., oxidation, deamidation, aggregation). All modules are validated with reference SHMT standards (recombinant or purified from natural sources) and include rigorous quality controls (system suitability, blank subtraction, and replicate analyses).

Unmatched Analytical Sensitivity, Specificity, and Mechanistic Insight

Our platform consistently delivers performance that surpasses typical industry and academic standards. In activity assays, we achieve signal‑to‑noise ratios > 300:1 at the LOD, with linearity over four orders of magnitude and Z’‑factors consistently > 0.8, making our assays highly robust for high‑throughput screening. Our kinetic fitting software uses global non‑linear regression to provide precise estimates of K_m and V_max, with residual errors < 2%. For protein quantitation by PRM, our chromatographic gradient resolves isoform‑specific peptides with retention time reproducibility < 0.5% RSD and peak area precision < 3%. In inhibitor studies, we perform full dose‑response curves with at least 8 concentrations in triplicate, and we provide Dixon plots and Cornish‑Bowden analyses to determine the mechanism of inhibition. Additionally, we offer isothermal titration calorimetry (ITC) to measure the binding thermodynamics of inhibitors, providing ΔH, ΔS, and binding stoichiometry with precision within ±2%. For clients requiring detailed structural insight, we perform hydrogen‑deuterium exchange mass spectrometry (HDX‑MS) to map ligand‑binding sites and conformational changes. This multi‑dimensional data set enables our clients to not only quantify SHMT activity but also to understand the molecular basis of substrate recognition, catalytic mechanism, and inhibition, facilitating the rational design of therapeutic strategies and biomarker applications.

Distinctive Advantages of Our SHMT Detection Service

Our service provides several unique benefits that directly address client challenges. First, we have developed matrix‑specific sample preparation protocols for a wide variety of SHMT sources—including tissue homogenates, cell lysates, clinical biopsies, and purified recombinant proteins—that effectively preserve enzyme activity and protein integrity, achieving recoveries > 95% for all tested matrices. Second, we maintain a comprehensive reference library of SHMT isoforms and their characterised kinetic, inhibition, and stability data, enabling rapid method setup and confident benchmarking. Third, we offer a rapid screening service using a microplate‑based activity assay that provides semi‑quantitative activity data within 1 hour of sample receipt—ideal for high‑throughput screening of compound libraries or patient cohorts. Fourth, our customised kinetic and inhibition studies can be tailored to simulate physiological conditions, including the presence of folate analogues and relevant cofactors. Fifth, we provide integrated data interpretation that links enzyme activity, isoform abundance, and inhibition profiles to biological or clinical outcomes (e.g., disease severity, drug efficacy), enabling clients to make informed decisions on candidate selection and patient stratification. Sixth, all our methods comply with ICH M10, FDA, and EMA guidelines on bioanalytical method validation, and we supply full validation dossiers (specificity, linearity, accuracy, precision, LOD, LOQ, robustness) along with detailed SOPs, ensuring that our data are readily accepted by regulatory authorities. Our team of enzymologists, metabolic biologists, and clinical researchers provides consultative interpretation, helping clients to design follow‑up experiments, predict in vivo efficacy, and support regulatory submissions.

Advanced Data Integration, Predictive Modeling, and Reporting

Our reporting transforms analytical data into strategic decision‑making knowledge. We deliver a comprehensive final report that includes: (i) an executive dashboard with key metrics (specific activity, K_m, IC₅₀, isoform ratio, and inhibitor mechanism) presented as concise scorecards; (ii) a detailed analytical section containing raw data, calibration curves, kinetic fits, and SPR sensorgrams; (iii) a statistical comparison of samples against reference standards or historical data, with p‑values and confidence intervals; and (iv) an interpretive narrative that contextualises the results—for example, explaining how a low IC₅₀ value indicates a potent and selective SHMT inhibitor, or how a shift in the SHMT1/SHMT2 ratio may reflect metabolic reprogramming in cancer. For clients with multiple compounds or patient cohorts, we provide multivariate analysis (PCA, PLS‑DA) to identify the most influential parameters and to guide selection. We also offer predictive models that estimate therapeutic efficacy or disease progression based on in vitro SHMT activity data, using our internally developed machine learning tools. All raw data files (e.g., .xlsx, .raw, .cdf) are supplied to ensure full transparency and re‑analysis capability.

Broad Applications Across Drug Discovery, Cancer Research, and Clinical Diagnostics

The versatility of our SHMT detection service spans a wide range of sectors. In pharmaceutical and biotech R&D, our assays are critical for target validation, lead optimisation, and selectivity profiling of one‑carbon metabolism modulators. In cancer research, we quantify SHMT activity and protein levels to understand metabolic dependencies and to evaluate the effects of chemotherapy and targeted therapies. In clinical diagnostics, we measure SHMT levels in patient samples to support the diagnosis and monitoring of metabolic and neurological disorders. In nutritional and folate research, our assays evaluate the impact of dietary factors on SHMT function. In quality control of biological reagents, we verify the activity and purity of SHMT standards. In academic research, our comprehensive profiling supports publication‑quality studies on enzyme regulation, structure‑function relationships, and metabolic pathways. In contract research organisations (CROs), our services provide robust data to support regulatory submissions. Our ability to tailor the analytical package to the specific isoform, sample type, and regulatory framework ensures that we serve a diverse global clientele with scientific rigour and practical relevance.

Commitment to Innovation, Quality, and Client Partnership

We are dedicated to advancing SHMT analytics through continuous technological improvement. Our current R&D includes the development of microfluidic‑based single‑cell activity assays for ultra‑sensitive detection, and the application of machine learning algorithms to predict inhibitor potency from chemical structure. We actively participate in inter‑laboratory proficiency testing for enzyme activity and protein analysis, and we contribute to the development of reference standards for one‑carbon metabolism enzymes. Our quality management system is ISO 9001 and ISO 17025 certified, and we follow GLP for all regulatory studies. We offer flexible engagement models—from single‑sample analysis to multi‑year collaborative projects—with dedicated project managers, volume discounts, and priority handling for time‑sensitive samples. Our global logistics provide specialised shipping kits (with stabilising buffers and temperature control) to preserve enzyme activity during transit. Turnaround times range from 1 business day for rapid screening to 12 business days for comprehensive kinetic, proteomic, and inhibition profiling. We maintain open communication, providing preliminary results upon request and final reports with expert commentary. Our success is measured by the confidence our clients have in their data and their ability to advance research, drug development, and clinical care. We invite you to partner with us to unlock the full potential of your SHMT research.

In summary, our serine hydroxymethyltransferase detection service delivers a comprehensive, precise, and application‑oriented analytical solution that integrates activity quantification, isoform discrimination, inhibitor screening, and stability assessment. By combining advanced instrumentation with deep expertise in one‑carbon metabolism and enzymology, we empower our clients to accelerate drug discovery, understand metabolic dysregulation, and improve diagnostic accuracy. We look forward to supporting your SHMT analysis needs with our state‑of‑the‑art analytical platform.